Akshat Jain: Key Takeaways from ASH2025: Transformative Therapeutics, Global Insight, and Compassionate Innovation
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared on LinkedIn:
“What an inspiring week at ASH2025 — the American Society of Hematology annual meeting in Orlando! Every year, this meeting reinforces why hematology is the beating heart of translational medicine. A few key takeaways that deeply resonated:

Transformative Therapeutics: The science behind novel agents continues to redefine how we treat human disease. The precision and creativity developed in blood disorders are now paving the way for breakthroughs across cancer, autoimmune, and metabolic diseases — a thrilling horizon for modern medicine.
Bench to Bedside in Action: Seeing how complex, chronic, and rare diseases are being approached with structured, risk-adapted protocols reminds me how rigor and compassion come together in true clinical innovation.
Industry: bouncing off ideas , laying Foundation for new collaborations and learning about pipeline always invigorate me.
Global Health Perspective: Hearing insights from colleagues across Europe, Asia, Africa, and beyond was humbling. The diversity in strategy, resource utilization, and patient response reminds us that innovation thrives when we listen, learn, and adapt globally.
Community and Collaboration: The best part — reconnecting with mentors, peers, and new collaborators. The exchange of ideas and the spark of potential partnerships always reignite my passion for research and patient care.

Grateful to be part of a field where discovery meets compassion every single day.
Thank you Andrea Fischer for keeping us informed and an amazing meeting.
Hemostasis Today, American Society of Clinical Oncology (ASCO), Blood Journals Portfolio bringing out timely reading.”
Stay updated with ASH25 updates with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines